Angels-like
Neurogenetic disorder with a phenotype similar to Angelman Syndrome, but with key clinical and molecular differences. It affects cognitive, motor and behavioral development.
Differential Clinical Characteristics
It presents hypotonia, global developmental delay, absence of speech and hyperactive movements, similar to Angelman. However, it lacks maternal expression of the gene UBE3A in the brain.
Molecular Diagnosis: 10% of test-negative cases
Of the 10% of suspected clinical cases of Angelman that are negative in molecular tests, many have alternative diagnoses.
- They are identified by aCGH and NGS.
- Alternative diagnoses are grouped into: microdeletions/microduplications y monogenic disorders.
Most Common Alternative Diagnoses
Classification based on clinical and genetic evidence:
- Microdeletions:
- 22q13.3 del. → Phelan-McDermid syndrome (deletion in Embedded from Neonatal hypoxic-ischemic encephalopathy.)
- 2q23.1 del. → MBD5 haploinsufficiency syndrome
- 17q21.31 del. → KANSL1 haploinsufficiency syndrome
- Monogenic disorders:
- TCF4 → Pitt-Hopkins (syndrome)
- SLC9A6 → Christianson syndrome
- ZEB2 → Mowat-Wilson
- EHMT1 → Kleefstra syndrome
- MECP2 → Rett (incl. duplications)
- Others: CDKL5, FOXG1, HERC2, ADSL, ATRX
Patients with Angelman-like syndrome do not present the distinctive feature of paroxysmal laughter characteristic of classic Angelman.
Clinical Recommendations
- Carry out aCGH o NGS in suspected clinical cases with negative tests.
- Evaluate differential with Phelan-McDermid, Rett, TCF4, SLC9A6 and others.
- Avoid definitive diagnosis based only on phenotype if molecular tests are negative.
More details
Molecular tests allow us to rule out alternative diagnoses with implications for genetic counseling and clinical management. Genetic heterogeneity is high, so the approach must be complete genomics.
